Literature DB >> 8759730

Somatic mutations in human Ig variable genes correlate with a partially functional CD40-ligand in the X-linked hyper-IgM syndrome.

D Razanajaona1, C van Kooten, S Lebecque, J M Bridon, S Ho, S Smith, R Callard, J Banchereau, F Brière.   

Abstract

X-linked hyper-IgM (HIGM-1) syndrome is a rare disorder resulting from mutations in the CD40-ligand (CD40L) gene. This defect is associated with normal or elevated serum levels of IgM, and with low to undetectable levels of serum IgG, IgA, and IgE. We analyzed the somatic mutation status in Ig V genes from three unrelated HIGM-1 patients by reverse-transcription PCR and sequence analysis. Two patients (B.S. and P.S.) expressed unmutated VH6 genes. In contrast, one patient (A.T.) was found to express mutated VH6 genes. Whether the presence of somatic mutations in this patient was related to a functional CD40L was assessed by deriving T cell clones from his peripheral blood cells. Upon activation, these T cell clones expressed weakly and transiently surface CD40L, and were able to induce limited isotype switch of normal native B cells, indicating residual CD40L function. Altogether, our results 1) confirm the central role played by CD40L in the generation of somatic mutation (patients B.S. and P.S.), 2) provide an unusual illustration of the relative dissociation between somatic mutation and isotype switching (patient A.T.), and 3) demonstrate a further complexity of the X-linked HIGM syndrome that may occur despite a partially functional CD40L.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759730

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

2.  Molecular mechanisms and selective influences that shape the kappa gene repertoire of IgM+ B cells.

Authors:  S J Foster; H P Brezinschek; R I Brezinschek; P E Lipsky
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

3.  CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans.

Authors:  S Weller; A Faili; C Garcia; M C Braun; F Le Deist F; G de Saint Basile G; O Hermine; A Fischer; C A Reynaud; J C Weill
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease.

Authors:  Cindy S Ma; Stefania Pittaluga; Danielle T Avery; Nathan J Hare; Irina Maric; Amy D Klion; Kim E Nichols; Stuart G Tangye
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

5.  CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis.

Authors:  D Gao; A H Wagner; S Fankhaenel; T Stojanovic; S Schweyer; S Panzner; M Hecker
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 6.  AID and Apobec3G haphazard deamination and mutational diversity.

Authors:  Malgorzata Jaszczur; Jeffrey G Bertram; Phuong Pham; Matthew D Scharff; Myron F Goodman
Journal:  Cell Mol Life Sci       Date:  2012-11-22       Impact factor: 9.261

7.  HIV vaccine development and broadly neutralizing antibodies.

Authors:  Neil S Greenspan; Ashutosh K Sheth; Vilok Desai
Journal:  Evol Med Public Health       Date:  2015-02-20

8.  TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.

Authors:  Véronique Godot; Colas Tcherakian; Laurine Gil; Iñaki Cervera-Marzal; Guangming Li; Liang Cheng; Nicolas Ortonne; Jean-Daniel Lelièvre; Giuseppe Pantaleo; Craig Fenwick; Mireille Centlivre; Hugo Mouquet; Sylvain Cardinaud; Sandra M Zurawski; Gerard Zurawski; Pierre Milpied; Lishan Su; Yves Lévy
Journal:  PLoS Pathog       Date:  2020-11-30       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.